BCR and inflammatory bowel disease: We performed 5’ immune profiling via single-cell RNA-Seq and BCR-Seq on S-PE–binding MBCs sorted from the B-cell enriched PBMCs of 3 people in the healthy control group, 5 patients with IBD treated with anti-TNF, and 4 patients with IBD treated with anti-IL-12/23 (Table 1), using matched samples from 3–4 months after dose 2 and from 3–4 months after dose 3 (Figure 1).